OVID — Ovid Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $219.51m
- $113.68m
- $0.39m
Annual cashflow statement for Ovid Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60.5 | -81 | 123 | -54.2 | -52.3 |
| Depreciation | |||||
| Non-Cash Items | 5.21 | 7.53 | 12.4 | 6.66 | 3.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.91 | 21.6 | -16.8 | -8.23 | 2.39 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -51.1 | -51.6 | 119 | -55.2 | -45.8 |
| Capital Expenditures | -0.244 | -0.391 | -0.189 | -1.42 | -0.137 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | -29.8 | 35 | -1.63 | -86.5 | -2.44 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -30 | 34.6 | -1.82 | -87.9 | -2.58 |
| Financing Cash Flow Items | — | -0.163 | -0.021 | 0 | 30 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 86.5 | 47.1 | 0.904 | 0.181 | 30.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.41 | 30.1 | 118 | -143 | -17.8 |